CONMED Corporation 2011 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company focused on surgical devices, equipment, and monitoring products used in arthroscopy, powered surgical instruments, electrosurgery, patient care, endosurgery, and endoscopic technologies. The filing covers the fiscal year ended December 31, 2011, with quarterly information for the fourth quarter. The company had approximately 3,400 employees and sold products in more than 100 countries. Approximately 50% of 2011 sales were generated outside the United States, and approximately 75% of revenue came from disposable products.
Key financial metrics
| Metric | 2011 | 2010 | Change |
|---|---|---|---|
| Net sales | $725.1 million | $713.7 million | Up 1.6% |
| Gross profit | $374.9 million | $365.4 million | Up $9.6 million |
| Gross margin | 51.7% | 51.2% | Up 0.5 percentage points |
| Income from operations | $8.3 million | $57.1 million | Down $48.8 million |
| Operating margin | 1.1% | 8.0% | Down 6.9 percentage points |
| Net income | $0.8 million | $30.3 million | Down $29.6 million |
| Diluted EPS | $0.03 | $1.05 | Down $1.02 |
| Cash from operating activities | $103.0 million | $38.2 million | Up $64.8 million |
| Capital expenditures | $17.6 million | $14.7 million | Up $2.8 million |
| Cash and equivalents | $26.0 million | $12.4 million | Up $13.6 million |
| Total debt | $143.5 million | $195.6 million | Down $52.1 million |
Gross margin benefited from favorable foreign exchange and product mix. Selling and administrative expense was essentially flat at $276.6 million, while research and development expense declined to $28.7 million from $29.7 million.
Material changes versus the prior comparable period
- Sales increased modestly, driven by higher single-use and reposable product sales, which rose 3.0% to $565.2 million. Capital equipment sales declined 3.2% to $159.9 million because hospitals continued to face capital-purchasing constraints.
- The aggregated Endosurgery, Electrosurgery, and Linvatec segment increased sales 2.2% to $610.1 million and expanded its operating margin to 14.6% from 12.9%.
- Patient Care sales declined 3.8% to $65.7 million, principally because of lower ECG electrode and IV device sales.
- Patient Care recorded a $60.3 million goodwill impairment charge in the fourth quarter, reflecting lower expected future earnings and pricing pressure. This reduced reported operating income and net income substantially.
- Endoscopic Technologies returned to profitability, reporting $0.3 million of operating income compared with a $1.3 million operating loss in 2010.
- The company repurchased $111.8 million of convertible senior subordinated notes at par following the November 2011 holder put. Only $0.3 million of those notes remained outstanding at year-end.
- The company repurchased $15.0 million of common stock during 2011 and had $108.8 million remaining under its authorized repurchase programs at year-end.
Liquidity, debt, and cash flow
Operating cash flow of $103.0 million materially exceeded net income because of the $60.3 million noncash goodwill impairment charge, working-capital improvements, depreciation, and amortization. Investing cash outflows were $21.7 million, including $17.6 million of capital expenditures and $4.2 million for acquisitions and intangible assets.
At December 31, 2011, the company had $80.0 million drawn on its $250.0 million revolving credit facility, $53.6 million outstanding under its term loan, and $9.6 million of mortgage debt. Approximately $160.2 million of revolving capacity was available, with approximately $9.8 million reserved for letters of credit. The company was in compliance with its credit agreement covenants.
Term-loan principal payments scheduled for 2012 totaled $54.6 million. Management expected approximately $20.0 million of 2012 capital expenditures and $2.0 million of pension contributions. The company stated that cash flow from operations, cash on hand, and available revolving capacity were expected to fund foreseeable operating needs, debt service, capital expenditures, and share repurchases.
Guidance, outlook, commentary, risks, and unusual items
- Management was cautiously optimistic about improving domestic economic conditions but noted continuing challenges in Europe and other international markets.
- Management expected restructuring costs of approximately $3.0 million to $4.0 million in 2012, following $3.5 million charged to cost of sales and $0.8 million charged to other expense in 2011.
- On January 3, 2012, CONMED entered into a 25-year sports medicine joint development and distribution agreement with the Musculoskeletal Transplant Foundation. The transaction included a $63.0 million upfront payment, potential additional payments of up to $84.0 million over four years, and financing through cash and revolving borrowings. CONMED receives 50% of MTF sports medicine allograft revenue and 100% of revenue from the platelet-rich plasma products.
- Key risks include competitive pricing pressure, healthcare cost-containment measures, hospital capital-spending constraints, foreign currency exposure, regulatory compliance and potential recalls, product liability and patent litigation, raw-material availability and pricing, acquisition integration, and restrictive debt covenants.
- The Affordable Care Act was expected to impose a 2.3% U.S. medical-device excise tax beginning in 2013. The company stated that inability to pass through this cost could adversely affect results and cash flow.
- Approximately $133.6 million of variable-rate long-term debt was outstanding at year-end. A 1.0% increase in comparable interest rates was estimated to reduce 2012 pretax income by approximately $1.1 million.
- Foreign exchange changes, net of hedging, increased 2011 sales by approximately $6.5 million and pretax income by approximately $1.2 million compared with 2010 rates.
- The fourth quarter of 2011 included the $60.3 million goodwill impairment charge; quarterly net loss was $25.1 million, or $(0.90) diluted EPS.
Important facts for investors to verify
- Assess whether Patient Care pricing pressure and declining sales represent a continuing operating problem beyond the goodwill impairment.
- Review the terms, accounting treatment, financing, and contingent consideration associated with the January 2012 MTF transaction.
- Verify the company’s ability to meet the $54.6 million of scheduled 2012 term-loan payments while funding the MTF transaction, capital expenditures, pension contributions, and share repurchases.
- Evaluate the sustainability of the $103.0 million operating cash flow, given that reported net income was only $0.8 million and included a large noncash impairment charge.
- Monitor the impact of the 2013 medical-device excise tax, healthcare reimbursement changes, hospital capital-spending trends, and foreign currency movements.
- Review restructuring progress and the estimated $3.0 million to $4.0 million of additional 2012 restructuring costs.
- Confirm regulatory, product liability, patent, and recall exposures, including the company’s stated $25 million per-incident and annual aggregate product liability insurance coverage.